- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05222464
Utilizing MyChart to Assess the Effectiveness of Interventions for Vasomotor Symptoms: A Feasibility Study
5 november 2022 uppdaterad av: Ottawa Hospital Research Institute
Utilizing MyChart to Assess the Effectiveness of Interventions for Vasomotor Symptoms: A Feasibility Study (REaCT-Hot Flashes Pilot)
Vasomotor symptoms (VMS) are a common consequence of systemic therapies for breast cancer.
Breast cancer treatments can cause VMS in approximately 30% of postmenopausal women and 95% of premenopausal women with early stage breast cancer (EBC).
There are many non-estrogen-based interventions available to manage VMS, including; lifestyle modifications, complementary and alternative medicine (CAM) therapies.
However, a recent systematic review and meta-analysis of pharmacological and CAM interventions conducted by our team, found no single optimal treatment for VMS management in breast cancer patients.
Given the complex patient, cancer and treatment variables influencing the experience of VMS, the numerous potentially effective VMS interventions available and the varying expectations for an effective intervention, the investigators believe Machine Learning (ML) is ideally suited to the analysis of this common and bothersome treatment related toxicity.
The EPIC electronic medical record, and MyChart application has provided both clinicians and patients with increased tools for the documentation of health related outcomes.
The investigators believe that the MyChart platform, and ML techniques can be utilized to collect, and analyze outcome data for breast cancer patients experiencing VMS.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Vasomotor symptoms (VMS) are a common consequence of systemic therapies for breast cancer.
Breast cancer treatments can cause VMS in approximately 30% of postmenopausal women and 95% of premenopausal women with early stage breast cancer (EBC).
In addition to their negative impact on quality of life, unmanaged VMS are the most common reason for discontinuation of potentially curative treatment in 25-60% of EBC patients.
Estrogen replacement is a common treatment for VMS in the general population, however, it is contraindicated in breast cancer patients.
There are many non-estrogen-based interventions available to manage VMS, including; lifestyle modifications, complementary and alternative medicine (CAM) therapies.
However, a recent systematic review and meta-analysis of pharmacological and CAM interventions conducted by our team, found no single optimal treatment for VMS management in breast cancer patients.
The investigators recently conducted a survey in 373 patients with EBC which found that while the majority of patients were interested in receiving an intervention to mitigate their symptoms, only 18% received a treatment for this problem.
In addition, more than one third of patients experiencing VMS report that they are not routinely asked about their symptoms in routine follow up.
Given the complex patient, cancer and treatment variables influencing the experience of VMS, the numerous potentially effective VMS interventions available and the varying expectations for an effective intervention, the investigators believe Machine Learning (ML) is ideally suited to the analysis of this common and bothersome treatment related toxicity.
Prior breast cancer studies have successfully applied to ML models to examine risk of developing breast cancer, as well as breast cancer prognosis.
The EPIC electronic medical record, and MyChart application has provided both clinicians and patients with increased tools for the documentation of health related outcomes.
The investigators believe that the MyChart platform, and ML techniques can be utilized to collect, and analyze outcome data for breast cancer patients experiencing VMS.
Studietyp
Interventionell
Inskrivning (Faktisk)
56
Fas
- Fas 4
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Ontario
-
Ottawa, Ontario, Kanada
- The Ottawa Hospital Cancer Centre
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Patients over the age of 18 who have histologically confirmed breast cancer, of any stage
- Patients experiencing vasomotor symptoms
- While the study is intended to evaluate the feasibility of the MyChart platform, patients without a MyChart account, who are interested in participating in the study, will have access to a paper or electronic email version. As participation in the MyChart program has benefits outside of this intended study, all patients without a MyChart account will be encouraged to sign up for the service
Exclusion Criteria:
- Those who are unable to complete questionnaires in English
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Övrig: Standard of Care Intervention
Standard of care intervention - The intervention will consist of 4 classes of standard of care treatments, namely, lifestyle modifications, complementary and alternative medicine (CAM) therapies, prescription medications, or adjustment of anti-cancer therapy.
|
Interventions will consist of 4 classes of standard of care treatments, namely, lifestyle modifications, complementary and alternative medicine (CAM) therapies, prescription medications, or adjustment of anti-cancer therapy.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Patient Engagement (MyChart Accessibility and User Experience)
Tidsram: 3 Months
|
Patient engagement will be defined by 60% of patients approached agreeing to participate in the study.
|
3 Months
|
Physician Engagement (MyChart Accessibility and User Experience)
Tidsram: 3 Months
|
Physician engagement will be defined by 60% of those completing the study log to approach patients for participation in study.
|
3 Months
|
Patient Accrual (MyChart Accessibility and User Experience)
Tidsram: 3 Months
|
Patient accrual will be defined by accruing 50 participants within 3 months.
|
3 Months
|
MyChart Utilization
Tidsram: Baseline and 6 weeks
|
MyChart utilization will be defined as 85% of participants completing both questionnaires (the Hot Flash Problem Score and the Composite Hot Flash Score) on the MyChart interface, and 50% of enrolled participants completing both questionnaires as per study protocol.
|
Baseline and 6 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Hot Flash Severity (MyChart Feasibility)
Tidsram: 3 Months
|
Hot flash severity (MyChart feasibility) will be assessed by the Hot Flash Problem Score, a composite score of the perceived distress, interference, and problematic nature of vasomotor symptoms (VMS) in daily life and by the composite hot flash score (assess hot flashes on a daily basis for 7 days).
The researchers will assess the feasibility of using MyChart to complete hot flash severity assessments by determining the percentage of participants who complete the tools as per protocol, including the percentage of patients who complete daily assessments over the 7 day period.
|
3 Months
|
MyChart Feasibility in assessing effectiveness of interventions for VMS
Tidsram: 3 months
|
The investigators will assess the effectiveness of an intervention by assessing change in hot flash severity scores using the Hot Flash Problem Score, and composite hot flash score from baseline to 6 weeks post intervention.
|
3 months
|
Effectiveness of Interventions for VMS - Traditional Statistical Modeling
Tidsram: 3 Months
|
Analyze MyChart questionnaire response data, using traditional statistical modelling (including linear and logistic regression models) to predict change in hot flash severity outcomes in response to interventions for VMS.
The severity outcomes will be based on two validated clinical tools.
These tools consist of the Hot Flash Problem Score (a composite score of the perceived distress, interference, and problematic nature of VMS in daily life), and Composite Hot Flash Score (this assess hot flashes on a daily basis for 7 days).
|
3 Months
|
Effectiveness of interventions for VMS (MyChart feasibility)
Tidsram: 3 Months
|
Effectiveness of interventions for VMS (MyChart feasibility) will be assessed by frequency of nocturnal awakenings, and toxicity data.
Data will be analyzed using traditional statistics and machine learning techniques to create a preliminary model predicting VMS treatment response in individuals.
|
3 Months
|
Predicting effectiveness of interventions for VMS - machine learning
Tidsram: 3 Months
|
Utilize machine learning models, including classification and regression trees, with comparison against standard regression models, to assess for improvements in predictive power for hot flash severity.
The researchers will use model explainability techniques, such as conditional dependence plots, to study the impact of specific features on the hot flash severity outcomes.
|
3 Months
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Utredare
- Huvudutredare: Sharon McGee, MD, The Ottawa Hospital Cancer Centre
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
25 februari 2022
Primärt slutförande (Faktisk)
22 juli 2022
Avslutad studie (Faktisk)
22 september 2022
Studieregistreringsdatum
Först inskickad
15 december 2021
Först inskickad som uppfyllde QC-kriterierna
24 januari 2022
Första postat (Faktisk)
3 februari 2022
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
8 november 2022
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
5 november 2022
Senast verifierad
1 november 2022
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- REaCT-Hot Flashes Pilot
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Bröstcancer
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital och andra samarbetspartnersAvslutadDen kliniska tillämpningsguiden för Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAvslutadBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAvslutadBreast Cancer Invasive NosSpanien
-
University Health Network, TorontoAvslutadBreast Cancer Invasive Nos | Primär invasiv bröstcancerKanada
-
Novartis PharmaceuticalsAvslutadMetastaserad bröstcancer (MBC) | Locally Advance Breast Cancer (LABC)Storbritannien, Spanien
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...OkändBRCA1-mutation | Breast Cancer Invasive NosPolen
-
McMaster UniversityCanadian Breast Cancer FoundationAvslutadBreast Cancer Invasive Nos | Steg 0 BröstkarcinomKanada
Kliniska prövningar på Standard of care treatments
-
Memorial Sloan Kettering Cancer CenterAvslutadFamiljer eller anhöriga till patienter som behandlas vid MSKCC för icke-kutana skivepitelcancer i | Övre matsmältningskanalenFörenta staterna
-
Instituto de Investigación Sanitaria AragónRekryteringDepressiv sjukdom | Ångeststörningar | Emotionell störning | Tillstånd efter covid-19Spanien
-
Jorge Javier Osma LópezUniversidad de Zaragoza; Instituto de Salud Carlos IIIHar inte rekryterat ännu
-
University of PittsburghAvslutadDepression | Ångest | Posttraumatisk stressyndrom | AlkoholmissbrukFörenta staterna
-
Jorge Javier Osma LópezHospital General Universitario de Castellón; Hospital Universitario La...Har inte rekryterat ännuInfertilitet | Emotionell störning | Ångest DepressionSpanien
-
Boston University Charles River CampusAvslutadÅngeststörningar | Emotionella störningar
-
Johns Hopkins UniversityRekryteringKompartmentsyndrom i ben | Extrakorporeal membransyresättningskomplikation | Extremitetsischemi, kritisk | ExtremitetsischemiFörenta staterna
-
Oklahoma State UniversityUniversity of Oklahoma; University of Minnesota; Case Western Reserve University och andra samarbetspartnersAvslutad
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) och andra samarbetspartnersAvslutadOproportionerlig form | Utökade fettkuddarFörenta staterna
-
Rhizen Pharmaceuticals SAIncozen Therapeutics Pvt LtdAvslutad